13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • KEYNOTE -555

    Acronym: 

    Keynote 555

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase I Tumour Stream Skin
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Melanoma & other skin
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Skin
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase-I randomized clinical study of Pembrolizumab (MK-3475) to evaluate the realtive bioavailability of subcutaneaous injection versus intravenous infusion in participants with advanced melanoma

    Lay Summary

    Sponsor / Cooperative group

    MSD

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Not Yet Recruiting